Alto Neuroscience, Inc.

ANRO Healthcare Biotechnology

In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.

22.07 0.55 −2.43%
Market cap
$887.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
14.85 20.52 15.69 15.42

+8 more quarters

Net Debt/EBITDA
7.78 9.10 9.32 7.80
Debt/Equity
0.09 0.08 0.13 0.20
Free Cash Flow per Share
(0.46) (0.84) (0.40) (0.37)
Book value per Share
5.12 7.40 5.24 4.12
Free Cash Flow
(19.76) (27.65) (11.52) (9.92)
Other line items

Show all line items

Columns are period end dates